Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results

Gut

Volumn 64, Issue 1, 2015, Pages 77-83

  Wyant, Tim ^a   Leach, Tim ^a   Sankoh, Serap ^a   Wang, Yuemei ^a   Paolino, Jonathan ^b   Pasetti, Marcela F ^c   Feagan, Brian G ^d   Parikh, Asit ^e  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e Takeda Pharmaceuticals International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4BETA7 INTEGRIN; CD4 ANTIGEN; CD45RO ANTIGEN; CHOLERA VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTEGRIN; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VEDOLIZUMAB; HEPATITIS B VACCINE; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; INFECTION; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE DRUG DOSE; ANTIBODY PRODUCTION; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRACT; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; MALE; YOUNG ADULT;

EID: 84904747073     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307127     Document Type: Article

References (27)

1. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330: 864-75.
2. Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol 1994; 153: 517-58.
3. Sheridan BS, Lefrançois L. Regional and mucosal memory T cells. Nat Immunol 2011; 12: 485-91.
4. Dubinsky MC Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-43.
5. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107: 1409-22.
6. Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2012; 21: 1216-20.
7. Brew BJ, Davies NWS, Cinque P, et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 2010; 6: 667-79.
8. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-507.
9. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-7.
10. Feagan BG, Rutgeerts PJ, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
11. Sandborn WJ, Feagan BG, Rutgeerts PJ, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.
12. Ahmed T, Arifuzzaman M, Lebens M. CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation. Vaccine 2009; 28: 422-9.
13. Sanchez JL, Trofa AF, Taylor DN, et al. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis 1993; 167: 1446-9.
14. Taylor DN, Cárdenas V, Perez J, et al. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Am J Trop Med Hyg 1999; 61: 869-73.
15. Sanofi Pasteur MSD. HBVAXPRO. Annex 1: summary of product characteristics. http://www.spmsd.com/wp-content/uploads/2011/12/HBVAXPRO-SMPC.pdf. Revised 11 July 2012. (accessed 29 Sep 2013).
16. European Medicines Agency. Dukoral. Annex 1: summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000476/WC500037570.pdf (accessed 29 Sep 2013).
17. World Heath Organization. Global alert and response (GAR): hepatitis B. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index4.html (accessed 29 Sept 2013).
18. Sanofi Pasteur MSD. Dukoral [product monograph]. http://www.cliniciansoftheworld.org/vaccine.pdf. Published November 2007 (accessed 29 Sep 2013).
19. Migasena S, Desakorn V, Suntharasamai P, et al. Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect Immun 1989; 57: 117-20.
20. Scerpella EG, Mathewson JM, DuPont HL, et al. Serum and intestinal antitoxin antibody responses after immunization with the whole-cell/recombinant B subunit (WC/rBS) oral cholera vaccine in North American and Mexican volunteers. J Travel Med 1996; 3: 143-7.
21. Schippers A, Kochut A, Pabst O, et al. β7 integrin controls immunogenic and tolerogenic mucosal B cell responses. Clin Immunol 2012; 144: 87-97.
22. Rahier J-F, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology 2010; 49: 1815-27.
23. Ravikumar R, Owen T, Barnard J, et al. Anti-TNF therapy in RA patients alters hepatitis B vaccine responses [abstract 827]. Presented at the American College of Rheumatology Annual Scientific Meeting 2006. https://acr.confex.com/acr/2006/webprogram/Paper5991.html (accessed 29 Sep 2013).
24. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, et al. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460-6.
25. Kobie JJ, Zheng B, Bryk P, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 2011; 13:R209.
26. Melmed GY Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009; 15: 1410-6.
27. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-9.